Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Novavax, Inc. (NVAX : NSDQ)
 
 • Company Description   
Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple studies.?Novavax developed its own coronavirus vaccine NVX-CoV2373. The company is currently marketing two versions of NVX-CoV2373, one marketed in partnership with the Serum Institute of India under the trade name Covovax and another version produced by Novavax and marketed under the trade name Nuvaxovid.?Novavax developed NanoFlu, its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix M adjuvant for senior patients aged 65 years and above.?ResVax a respiratory syncytial virus vaccine is being developed to protect infants by immunizing mothers against the disease. Novavax is discussing the opportunity to bring ResVax to the market globally with the help of commercial partners.

Number of Employees: 1,541

 
 • Price / Volume Information   
Yesterday's Closing Price: $58.43 Daily Weekly Monthly
20 Day Moving Average: 5,818,699 shares
Shares Outstanding: 78.14 (millions)
Market Capitalization: $4,565.40 (millions)
Beta: 1.59
52 Week High: $277.80
52 Week Low: $41.33
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 19.73% 34.86%
12 Week -26.92% -19.65%
Year To Date -59.16% -50.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
21 FIRSTFIELD ROAD
-
GAITHERSBURG,MD 20878
USA
ph: 240-268-2000
fax: 240-268-2100
ir@novavax.com http://www.novavax.com
 
 • General Corporate Information   
Officers
Stanley C. Erck - President and Chief Executive Officer
James F. Young - Chairman of the Board of Directors
James P. Kelly - Executive Vice President; Chief Financial Officer
Gregg H. Alton - Director
Richard H. Douglas - Director

Peer Information
Novavax, Inc. (CORR.)
Novavax, Inc. (RSPI)
Novavax, Inc. (CGXP)
Novavax, Inc. (BGEN)
Novavax, Inc. (GTBP)
Novavax, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 670002401
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
Share - Related Items
Shares Outstanding: 78.14
Most Recent Split Date: 5.00 (0.05:1)
Beta: 1.59
Market Capitalization: $4,565.40 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $5.71 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $25.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/04/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 2.27
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 69.88
Price/Cash Flow: -
Price / Sales: 3.25
EPS Growth
vs. Year Ago Period: 183.93%
vs. Previous Quarter: 122.90%
Sales Growth
vs. Year Ago Period: 57.41%
vs. Previous Quarter: 216.82%
ROE
03/31/22 - -572.54
12/31/21 - -368.20
09/30/21 - -149.66
ROA
03/31/22 - -49.13
12/31/21 - -66.43
09/30/21 - -45.23
Current Ratio
03/31/22 - 1.04
12/31/21 - 0.90
09/30/21 - 1.24
Quick Ratio
03/31/22 - 0.99
12/31/21 - 0.90
09/30/21 - 1.24
Operating Margin
03/31/22 - -93.91
12/31/21 - -152.12
09/30/21 - -89.31
Net Margin
03/31/22 - -93.91
12/31/21 - -152.12
09/30/21 - -89.31
Pre-Tax Margin
03/31/22 - -91.86
12/31/21 - -149.57
09/30/21 - -88.26
Book Value
03/31/22 - 0.84
12/31/21 - -4.65
09/30/21 - 6.19
Inventory Turnover
03/31/22 - 0.57
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - -
09/30/21 - 0.70
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - -
09/30/21 - 41.19
 

Powered by Zacks Investment Research ©